ZimVie (ZIMV) Competitors $18.94 +0.06 (+0.32%) Closing price 04:00 PM EasternExtended Trading$18.94 +0.00 (+0.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZIMV vs. AORT, EYE, ENOV, CNMD, NVCR, SSII, ESTA, CDRE, BLFS, and PLSEShould you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), SS Innovations International (SSII), Establishment Labs (ESTA), Cadre (CDRE), BioLife Solutions (BLFS), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry. ZimVie vs. Its Competitors Artivion National Vision Enovis CONMED NovoCure SS Innovations International Establishment Labs Cadre BioLife Solutions Pulse Biosciences ZimVie (NASDAQ:ZIMV) and Artivion (NYSE:AORT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do analysts rate ZIMV or AORT? ZimVie currently has a consensus target price of $17.75, indicating a potential downside of 6.28%. Artivion has a consensus target price of $40.63, indicating a potential downside of 6.96%. Given ZimVie's higher probable upside, equities analysts plainly believe ZimVie is more favorable than Artivion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZimVie 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Artivion 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, ZIMV or AORT? ZimVie has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ZIMV or AORT? 95.6% of ZimVie shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 5.4% of ZimVie shares are held by insiders. Comparatively, 8.1% of Artivion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ZIMV or AORT more profitable? ZimVie has a net margin of -4.39% compared to Artivion's net margin of -4.43%. ZimVie's return on equity of 6.37% beat Artivion's return on equity.Company Net Margins Return on Equity Return on Assets ZimVie-4.39% 6.37% 3.34% Artivion -4.43%5.70%2.29% Which has preferable valuation & earnings, ZIMV or AORT? Artivion has lower revenue, but higher earnings than ZimVie. Artivion is trading at a lower price-to-earnings ratio than ZimVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimVie$449.75M1.19-$25.83M-$0.70-27.06Artivion$388.54M5.30-$13.36M-$0.42-103.98 Does the media prefer ZIMV or AORT? In the previous week, Artivion had 6 more articles in the media than ZimVie. MarketBeat recorded 11 mentions for Artivion and 5 mentions for ZimVie. ZimVie's average media sentiment score of 1.51 beat Artivion's score of 0.84 indicating that ZimVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZimVie 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Artivion 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZimVie beats Artivion on 9 of the 17 factors compared between the two stocks. Get ZimVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIMV vs. The Competition Export to ExcelMetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$532.43M$11.00B$5.75B$9.77BDividend YieldN/A1.84%6.66%4.50%P/E Ratio-27.0621.6182.5826.38Price / Sales1.1931.30535.42110.80Price / Cash10.1625.1325.7028.92Price / Book1.293.4511.196.58Net Income-$25.83M$211.94M$3.28B$265.84M7 Day Performance-0.16%-1.16%0.15%-0.07%1 Month Performance0.96%13.38%8.34%5.83%1 Year Performance9.23%-8.99%54.21%17.88% ZimVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIMVZimVie0.707 of 5 stars$18.94+0.3%$17.75-6.3%+8.9%$532.43M$449.75M-27.061,770News CoveragePositive NewsHigh Trading VolumeAORTArtivion3.2854 of 5 stars$43.53-2.9%$40.63-6.7%+61.6%$2.12B$388.54M-103.641,600EYENational Vision3.4718 of 5 stars$23.93-3.6%$24.73+3.3%+117.2%$1.97B$1.82B-132.9413,411Positive NewsENOVEnovis4.3763 of 5 stars$30.98-1.5%$51.00+64.6%-33.7%$1.80B$2.11B-2.177,367Positive NewsCNMDCONMED4.541 of 5 stars$54.35-2.6%$59.80+10.0%-25.8%$1.73B$1.33B15.403,900Positive NewsNVCRNovoCure4.0566 of 5 stars$11.70-5.9%$28.79+146.0%-36.6%$1.39B$605.22M-7.501,488News CoverageSSIISS Innovations InternationalN/A$6.98-0.1%N/AN/A$1.35B$27.62M0.004ESTAEstablishment Labs1.9857 of 5 stars$40.66-6.8%$56.50+39.0%-9.9%$1.26B$177.42M-13.331,018News CoverageCDRECadre3.3799 of 5 stars$30.27-2.5%$31.50+4.0%-14.9%$1.26B$567.56M32.212,284Positive NewsBLFSBioLife Solutions1.7514 of 5 stars$25.65-1.0%$31.29+22.0%-3.2%$1.24B$82.25M-213.73440Positive NewsPLSEPulse Biosciences4.0067 of 5 stars$16.49-3.3%$22.00+33.4%-16.6%$1.15B$700K-15.70140Positive News Related Companies and Tools Related Companies Artivion Competitors National Vision Competitors Enovis Competitors CONMED Competitors NovoCure Competitors SS Innovations International Competitors Establishment Labs Competitors Cadre Competitors BioLife Solutions Competitors Pulse Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIMV) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZimVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
